Summary: A first step in the quantification of receptor density in the living human brain is the measurement of the binding of a labeled ligand to the receptor in question.
steady-state rate of accumulation and the volume of dis tribution of labeled NMSP in the caudate nucleus. The average value of k3 in the 11 normal volunteers was 0.065 min -I. The fractional clearance of labeled N MSP from the caudate nucleus (k2) was 0.070 min -I and thus close to the value of k1• We also examined several indexes of binding based on ratios between different regions in brain. The indexes required that binding be negligible compared to the efflux of labeled NMSP (i.e., k2 :P k3) and therefore yielded incorrectly low values of k3• Thus, the only accurate approach used measured plasma con centrations to estimate transfer constants at steady state and yielded the absolute rate of binding k3• The approach is applicable to other irreversibly bound ligands. Key Words: Dopamine-N-Methylspiperone-Neurore ceptors-Pharmacokinetics-Positron emission tomog raphy. (Wagner et al., 1983; Burns et aI., 1984 ; Farde et al., 1985a; Samson et al. , 1985) . Relative receptor densities in different parts of the brain can be assessed as the ratio of total binding (specific and nonspecific) to nonspecific binding. In the case of D2 dopamine receptors in the caudate nucleus, a region rich in these receptors in humans and primates, the caudate radioactivity can be compared with the activity in the cerebellum, which has no such receptors. The ratio of radioac tivity in caudate and cerebellum has been noted to rise as a linear function of time in normal vol unteers and in patients with neuropsychiatric diseases. Using 3-N-[IIC]methylspiperone ([IIC]NMSP), we observed a marked decline with age of the caudate-cerebellar radioactivity ratio in 44 normal male and female volunteers .
In the present report, we describe the accumula tion of NMSP with the ultimate purpose of mea suring receptor density directly. The mathematical description was based on a three-compartment model of the brain (Sokoloff et a\., 1977; Gjedde, 1982; Brooks et a\., 1984; Mintun et a\., 1984) . This approach does not require separate measurements of cerebral blood flow, blood volume, or labeled metabolites of NMSP in brain or blood.
METHODS

Theory
The accumulation of "C-Iabeled NMSP in a brain re gion of interest occurs in two steps: The ligand first crosses the blood-brain barrier (capillary endothelium) and later binds to the receptors of interest in the region, as well as to other possible sites. The following reactions symbolize these events: .
K, where Ca is the concentration of the ligand in arterial plasma, Mf the quantity of drug in the exchangeable pool of the tissue, Mh the quantity of drug bound to the re ceptors of interest (e.g., D2 dopamine receptors), and Mr the quantity of drug bound to other secondary or non-D2 dopamine receptors. The scheme actually includes four compartments, but the compartments of Mr and Mr (by definition) equilibrate rapidly to form one etIective com partment.
[We chose the convention of "quantity" (de noted by the symbol M) to be distinguished from "con centration" (symbol C) because true concentrations are unknown for the various cellular and extracellular com partments lumped by the method of external counting.] The term K, symbolizes the rate of clearance of the ligand from the circulation, equal to the product of the extraction fraction and the flow rate of the fluid compart ment in blood that contains the tracer (Crone, 1963) :
where PS is the product of the permeability of the ligand and the endothelial diffusion area, E the extraction frac tion of unidirectional transfer, and F the tracer source fluid (blood plasma) flow rate per unit volume of the brain region of interest.
The term k2 is the fractional clearance of the ligand from the region of interest to the perfusing fluid:
where A. is the coefficient of partition of the ligand be tween tissue and perfusing fluid (ml g-I). The term k3 is the rate constant for the association of the ligand with the receptors of interest in the region, equal to the product of the bimolecular association con stant and the quantity of receptor sites:
where ko n is the bimolecular association constant, B;"'ax the quantity of receptor sites available for binding, and
Vd the physical distribution volume of the ligand. The term B;"'ax is used to represent unoccupied receptors, while Bmax is the total number of receptors, some of which may be blocked by endogenous ligands and neuro leptic drugs. The term k4 represents the rate of dissociation from the receptor, which takes into account both the molecular dissociation rate and the number of available receptors as the number of occupied receptors increases:
where korr is the molecular dissociation rate, Cr the con centration of unbound ("free") ligand, and KD the disso ciation constant, equal to the ratio between kofr and kon.
When Cr is negligible compared to KD,
The terms k, and k6 represent "additional," secondary, reversible binding in the region. Whether the additional, secondary binding is specific or not, the kslk6 ratio de fines an apparent expansion of the distribution of the li gand in brain. In analogy with Eq. 2, we call this ratio p:
where p is the index of the magnitude of a rapidly equili brating space. Equations 3 and 4 originate in the differen tial equation describing the binding of ligand to receptor:
where Mr is the quantity of ligand free in the tissue and equal to the product of Cr and Vd and Mb is the quantity of labeled ligand bound to receptorsl. When terms are rearranged,
since, according to Eq. 7,
In Eqs. 7 and 9, B;"'ax is considered a constant (as it is elsewhere in the article). The terms have been combined in the particular form of Eq. 9 to indicate that k3 and k4
are real parameters of the differential equation (note that k3 is always a constant in time and that k4 is a constant when Mr remains constant, regardless of the magnitude of Mf). This point is not clear from Eq. 7 and prompted the definitions of k3 and particularly k4 expressed in Eqs.
3 and 4.
The fluxes between the four original compartments can be described by linked differential equations. In the fol- 
the solution to Eqs. 10-12 was given by Gjedde (1982) :
where
The volume Vr is the "kinetic" distribution volume of the ligand equal to the steady-state ratio between MiT) and Ca(n and to the fraction K/(k2 + k3). and where e(n is the normalized integral L [Ca(t)dt/ Ca(T)], and VeT) the total distribution volume equal to the ratio between M(T) and Ca(T). Thus, under the assumption of negligible dissociation of the ligand from the receptor in question, the solution predicts that the relation between VeT) and the normal ized integral e(T) will be linear after the onset of steady state, with a slope of ex equal to the product of kJ and Vr and an ordinate intercept of ViI + p)kzf(k2 + k3): ko
In an "inert" region (e.g., cerebellum) where no satu rable, specific binding is believed to occur (i.e., k3 = 0, P = 0), Eq. 17 reduces to an expression in only one vari able, A:
where Vo(T) is the steady-state volume of distribution in the "inert" region. Equations 17 and 18 predict that the apparent volume of distribution of the ligand in a region where the ligand is trapped irreversibly increases linearly as a function of e(T), while in a region of no binding it remains constant, equal to the brain-blood partition coefficient after the onset of steady state.
Determination of k3
As defined above, k3 = ex Vf. There are four steps to the calculation of k3, two involving the determination of A and ex and two involving the determination of Vf:
(a) The first step is the measurement of A in an "inert" region. The step involves the regression of the distribu tion volume of the ligand (the tissue-plasma radioactivity ratio) to the normalized integral of the ligand concentra tion in blood plasma (e).
(b) The second step is the correction of blood plasma radioactivities for the presence of labeled metabolites on the basis of A. The step yields the correct blood plasma radioactivities of the ligand that are necessary to calcu late the correct values of e. Determination of partition coefficient. Equation 17 predicts that the steady-state ratio between radioactivity in cerebellum and plasma will be constant and equal to the apparent partition coefficient of the ligand. For times greater than the time of onset of steady state (T > To), this ratio cannot decline in the absence of labeled metab olites in plasma or brain. Thus, when the ratio between radioactivity in cerebellum and plasma declines as a function of time after the onset of steady state, spurious counts must be appearing in the plasma and/or brain, and if they appear in brain, the excess radioactivity must orig inate from metabolites having a brain-blood partition co efficient lower than the ligand itself.
Labeled metabolites of the ligand may appear in blood plasma and subsequently cross into brain, and labeled metabolites may be produced in brain and subsequently cross into the circulation from which they may again dif fuse into brain. Thus, spuriously high radioactivity may be observed in both brain and plasma. The metabolites may be hydro-or lipophilic and may or may not bind spe cifically to the receptors of interest or other receptors in brain. For the remainder of the analysis, we assume only that (a) metabolites do not bind irreversibly to receptors or otherwise in the brain and (b) the partition coefficient of labeled metabolites is the same for all regions.
The labeled metabolites can be divided into two types. The first are those that come to equilibrium during the period of the scan (i.e., reach a constant ratio between brain and plasma concentrations). They affect the esti mate of the "average" partition coefficient of NMSP.
However, they do not affect the measurement of k3 when they do not affect the steady-state rate of accumulation of label. The second type of labeled metabolites are those that do not achieve equilibrium during the positron emis sion tomography (PET) scan. They contribute to a de cline or a rise of the cerebellar volume of distribution. The magnitude of this deviation depends on the relative concentrations of these nonpenetrating metabolites in plasma and brain tissue.
We observed that the cerebellum-plasma radioactivity ratio of NMSP always declined linearly with e(T) after some time. To correct for the metabolites of the second type mentioned above, the plasma concentrations were reduced mathematically to values that yielded constant cerebellum-plasma ratios after that time. The estimate of A, the partition coefficient, was obtained by fitting the radioactivity ratio between cerebellum and plasma to an equation describing the monoexponential approach to, and subsequent linear decline from, a steady-state volume of distribution equal to the partition coefficient:
where Vapp(n is the apparent volume of distribution of the labeled ligand in the cerebellum in the presence of metabolites in tissue or blood, aapp the rate of linear de cline of this volume from A as a function of 8app(n, and Tapp a time constant describing the approach to the steady-state distribution volume. An equation of this form will later be applied also to the regions of binding (see Eq. 21). The regression of pairs of Vappcn and 8app(n by Eq. 19 yielded estimates of A, aapp' and Taw Correction (�lplasma concentrations. The plasma con centrations of the ligand were corrected for the contribu tion of labeled metabolites of the ligand by reducing the plasma concentrations to values that resulted in constant cerebellum-plasma ratios after the onset of steady state:
where Capp(n is the total radioactivity in plasma and Ca(n the concentration of the labeled ligand. On the basis of the plasma concentrations of the ligand, correct values of 8(n and V(n were computed for the regions of interest.
Determination of steady-state rate of hinding. The third step was the estimation of the slope of the linear increase of the regional distribution volume as a function of the normalized integral calculated on the basis of cor rect plasma radioactivities. Measured pairs of regional V(n and 8(n were regressed by the equation describing the (approximate) monoexponential approach of a func tion towards an asymptote (T):
Equations 19 and 21 were derived from the two distinct asymptotes of the function V(n of 8(n, represented by the tangent of the function through the origin (the slope of which is K,) and the steady-state asymptote (the slope of which is a) that may or may not be reached in the time of study. Since the value of K, must equal to or exceed that of a, K, can always be represented by the expression a + (l3/p), where p is any value with unit of time. When the approach of V(n toward the steady-state asymptote is approximately monoexponential, which is usually the case, then the approach can be represented by Eq. 21, where T equals p (exactly). The approximation to a monoexponential function is analogous to the representa tion of plasma concentration by a sum of exponentials (Huang et aI., 1980) . According to Eq. 17, the slope a represents the product k3 Vr, i.e., the product of the binding rate ko nB ;"ax and the volume of distribution of the unbound com pounds (Vr). The ordinate intercept (13) to which the func tion V(n of 8(D tended for times greater than the time of onset of steady state, is a volume that combines the volumes of distribution of all labeled forms of the original
compound not bound irreversibly in the tissue, including possible labeled metabolites in the region of interest, pro vided such labeled metabolites do not bind irreversibly to the receptors of interest or any other binding or trapping mechanism. In the absence of labeled metabolites, re ceptors other than the receptors of interest, and nonspe cific binding, 13 equals the ratio Vl/A (Eq. 17).
Calculation of kj• The term k3 is the ratio between the slope (a) and the distribution volume (Vr). The three rate constants K" kz, and k3 must be calculated simulta neously from the estimates of a, 13, T, and A. While a is the slope of the terminal asymptote of the function V(n, K, is the slope of the initial rise of V(n as a function of 8(n. The term k2 is the ratio between K, and A, and kl can be calculated from K" kz. and a, where a equals the steady-state clearance K,k3/(kz + k3) (Eq. 16). To sim plify the calculation of K" k2, and k3, we introduced the term 0 for the ratio A/Vf:
A aT
which follows from Eq. 16 and the definition of Vf:
With the aid of the term 0, the three transfer constants were calculated as follow:
In Eq. 24, K, was defined as the value of the derivative of Eq. 21 for 8(D equal to zero (i.e., the tangent through the origin).
The value of p, the index of rapidly reversible binding in the region of interest, was calculated from the defini tion of the ordinate intercept of Eq. 21 given in Eq. 17:
Ratio index of k3 (27) Several modifications of the fundamental Eqs. 17 and 18 have been said to yield indexes of binding on the basis of the ratio of radioactivities in a region of interest and an "inert" region. We discuss the usefulness of the ratio in dexes in the Discussion section.
Experimental procedures
Studies were performed in normal male volunteers aged 18-38 years. Informed consent was obtained in compliance with the Johns Hopkins Clinical Investigation Committee. Each subject was screened for normality by medical history, physical exam, neuropsychological testing, electrocardiogram, and blood tests.
Each PET scan was performed in the manner pre viously outlined (Wong et aI., 1984) : Each subject re ceived a prior noncontrast x-ray computed tomography scan for scanner alignment. Each PET scan began with the injection of 18-20 mCi "C-labeled NMSP into an an-tecubital vein. The injection lasted 30 s, followed by an intravenous flush lasting 2-3 min. Blood samples were obtained from the dorsal vein of the contralateral hand heated to 44-50DC. Plasma samples were obtained by centrifugation and counting in a gamma scintillation spectrometer. The NMSP was labeled by the method previously described (Burns et ai., 1984) . Specific activi ties averaged 1,000-2,000 Ci mmol-l at the time of syn thesis. The injected mass averaged 4-15 /-Lg total (0.06-0.21 /-Lg kg-l body weight), determined by HPLC. The emitted radioactivity was recorded with the NeuroEcat positron camera (CTI) in the high-resolution mode. Ra dioactivity was simultaneously detected in the caudate nucleus, cerebellum, and frontoparietal cortex in the three planes of the scanner for 1.5 h after the time of injection of the tracer.
Regions of interest were drawn over the head of the caudate nucleus and the cerebellar cortex. The PET mea surements were all recorded as microcuries per milliliter of brain and reflected the average of paired regions of the left and right sides. The weight of 1 ml brain was assumed to be equal to 1 g. All results were therefore referred to milliliters or grams of brain solely on the basis of conven tion.
In three subjects, metabolites of NMSP in plasma and the percentage of actual NMSP labeled by IIC were de termined by HPLC. Typically, three to five plasma samples were separated during the 1.5-h imaging period. The percentage of metabolites was used to correct the total radioactivity detected in plasma in these three cases by linear interpolation between the measured points. The results were compared with the model-dependent correc tion described above.
The volume of distribution was determined as the ratio of the brain tissue radioactivities divided by the plasma radioactivities.
All PET analyses were initially acquired on a PDP 11/60 peripheral data processor (DEC) and further pro cessed on a Tektronix 4042 microcomputer and main frame computers that included the VAX 11/780 (DEC) at the Panum Institute in Copenhagen and the IBM 4341 at the Johns Hopkins Medical Institutions.
RESULTS
We applied a simple three-compartment model to the binding of labeled NMSP to receptors in the human caudate nucleus. Within the time of studies, the form of the function V(n of Sen, expressed in the operational Eq. 17, revealed that the steady state accumulation of labeled NMSP was irrevers ible, the binding parameter k3 actually constant, and k O ff' the rate constant of molecular dissociation, negligible (i.e., k4 small compared with k3)' The steady-state slope of the function V(n of S(n was therefore proportional to B:na x , the quantity of re ceptors available for irreversible binding. Figure 1 gives a typical example of the radioac tivities actually observed in the caudate, cere bellum, and frontal cortex of one normal volunteer. Subsequent calculations were made from original data of this form. ..
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Caudate
Frontal Cortex Figure 2 shows the ratio of radioactivities of the caudate nucleus and cerebellum as a function of time. As indicated in Eq. 29 and Ta ble 2 (see Dis cussion section), the slope of the linear regression of the ratio as a function of time equaled k3 V r8(7)1 X-T. Since k3' Vr, and X-are constants, the linearity of this slope implied a constant ratio between S(n and T. This meant that the plasma concentration of the ligand could be described as a power function of T where Ca(n = aT-b.
The recorded radioactivities were converted by Eq. 19, which expresses the volume of distribution ex (ml g-I min-I)
(mig-I)
T (min)
Vr ( of the ligand as a function of the normalized inte gral of radioactivity in plasma. As an example of graphs of VeT) as function of OCT), both caudate nucleus and cerebellum of one typical volunteer are shown in Fig. 3 . The distribution of the ligand in cerebellum always tended toward a linear function of O(T) that declined at the average rate of -0.010 ± 0.00 1 min-1 (SEM; n = 11). The average value of the brain-blood partition coefficient, equal to the ordinate intercept estimated by Eq. 19, is listed in Ta ble 1. V sing the decline of the cerebellar distribution, the "arterialized" venous plasma radioactivities were corrected for the presumed presence of me tabolites by Eq. 20. In some volunteers, total plasma radioactivities were also corrected for the presence of metabolites by HPLC. Representative Fig. 4 . Since the model-cor rected and HPLC-corrected plasma concentrations were similar, the concentration of metabolites in brain metabolites probably was low. On the basis of the calculated, correct ligand concentrations in ar terial plasma, new values of VeT) and OCT) were calculated.
A typical relationship between O(T) and T is shown in Fig. 5 , illustrating the linear relationship after the onset of steady state. Although this lin earity may help explain the empirical finding that the caudate/cerebellar is linear with time (see Dis cussion section, Eq. 29), the presence or absence of this linearity between 0 and time is not required for the validity of the general model presented in this paper. When the plasma curves are fit to a power func tion, the mean value of b (the numerical value of the power of T in the power function aT-h) for the 11 volunteers was 0.56 + 0.06 (SEM; n = II), cor responding to a 8(T)/T ratio of 2.3.
Pairs of VeT) and 8(T) were fitted by Eq. 21 and the resulting regressions shown in Fig. 6 for all 11 subjects. The estimates of a, f3, and T were listed in Ta ble 1. Values of Vf, K], k2, k3' and p were calcu lated from Eqs. 23-27, using the estimates of a, f3, A, and T and listed in Ta ble 1. The listed value of k3 is the direct estimate of the konB'max product.
DISCUSSION
The present article introduces a mathematical model describing irreversible binding of radiola beled ligands to receptor-rich regions of the brain. The model predicts the rate of binding of the la beled ligand to its receptor (k3) and permits compar ison of binding in a nonreceptor area (e. g. , the cere bellum) to binding in a receptor area (e. g. , caudate nucleus). The accumulation constant k3 must be known to calculate the quantity of receptors avail able for the binding of the ligand. In the present article, estimates of k3 were obtained from the four measurable parameters a, f3, A, and T defined in Eqs. 2, 16, and 21.
The results indicate that the magnitude of k3 is so large compared with that of k2 that determination of k3 from steady-state solutions of the differential equations is the only correct derivation of k3• To calculate the magnitude of k3 in this way, we con verted the actually observed radioactivities to volumes of distribution (V) as function of the nor malized time integral (8). The procedure did not distinguish between metabolites in plasma and brain (see following discussion) and allowed esti mation of KJ, the unidirectional clearance of the li gand from the blood to the brain. The agreement between the model-corrected and HPLC-corrected plasma concentrations suggests low brain metabo lite levels. Arnett et al. (1985) reported that brain metabolites of [ l 8F]NMSP represent 5-10% of the total activity in rodent cerebellum and striatum. The relatively unchanging mass of ligand in the tissue suggests that similarly slow metabolism may also characterize [lIC]NMSP in brain. Hence, the agreement between the model-and HPLC-cor rected plasma concentration observed in the present study (assuming metabolite levels to be negligible also in human brain) is not unexpected. Several spiroperidol and NMSP binding sites have been identified in the literature. The present study revealed only high-affinity (irreversible) binding sites with half-times of dissociation in the order of hours. Additional, irreversible binding was lumped into a single index, called p in the present article.
Several points distinguish the present approach from those of previous studies. The present ap proach represents essentially the first complete ki netic analysis of human neuroreceptor binding. Previous studies can be divided into non-steady state ("transient") (Gjedde et aI., 1986) and steady state analyses. The present analysis is based on a steady-state solution that not only provides a graphical indication of the important parameters but also may furnish more stable estimates of these parameters (Patlak et aI., 1983; L. Bass, personal communication) than do transient analyses. The "graphic" slope-intercept plot of the steady-state solution to the three-compartment model (Gjedde, 1982; Patlak et aI., 1983) grew out of a similar solu tion to a two-compartment model (Gjedde, 1981) .
Of the steady-state approaches recently pro posed in the literature (e.g., Patlak and Blasberg et aI., 1985) , we consider the present method more general and appropriate for ligands subject to irre versible binding because other methods require the magnitude of k3 to be negligible compared with the magnitude of k2• Equilibrium methods (e.g., Farde et aI., 1985b) do not yield quantitative estimates of the distribution of unbound ligand in the region of binding (a nonbinding region is substituted for this purpose) and do not consider secondary, rapidly equilibrating binding sites, which may exist for all ligands to a greater or lesser extent.
Kinetic analyses are frequently said to require that blood flow and P S product be known explicitly (Mintun et aI., 1984; Frey et aI., 1985) . However, we argue that the transfer constants K l and k2 (as we defined them) determine the net flux of tracer across the blood-brain barrier for all times from the injection to steady state. The net flux equals the difference between the products K l Ca(t) and k2 Mt<t) for all values of t (Gjedde, 1982 ; also see foot note 1) and renders the independent measurement of PS product and flow unnecessary, and possibly undesirable from the points of view of error propa gation and dosimetry.
In the present as well as previous studies, labeled metabolites of the ligand may appear in plasma and brain tissue. To deal with metabolites in plasma or tissue that did not readily cross the blood-brain barrier, we calculated a correction factor for the measured plasma concentrations that led to a con stant ratio of radioactivity between cerebellum and plasma as a function of the normalized time integral of [ l lC]NMSP in plasma.
The correction factor was determined by as suming no metabolites at the time of injection and was equal to the ratio between the observed de-clining ratio between cerebellum and plasma and a constant ratio consistent with steady state for NMSP and its labeled metabolites in tissue and plasma (see Fig. 3 ). The ordinate intercept of both functions (i.e., the declining cerebellum-plasma ratio and the constant cerebellum-plasma ratio) was obtained by extrapolation to zero time when metabolites did not yet exist. The intercept repre sented the partition coefficient for NMSP that would have been measured in the absence of me tabolites that did not equilibrate during the period of the scan. This method of metabolite correction accounted for both brain and plasma metabolites and established an average partition coefficient for the tissue. Thus, metabolites that did not equili brate during the scan were not allowed to con tribute to the magnitude of k3 determined at steady state, while metabolites that did equilibrate did not contribute if they did not bind irreversibly to the receptors in question, or to any other site. Under this assumption, the only contribution to the net accumulation was [11C]NMSP.
Previous non-steady-state (e .g., Brooks et aI., 1984; Mintun et aI., 1984) , steady-state (Patlak and Blasberg, 1985) , or equilibrium (Farde et aI., 1985a, b) studies did not explicitly discuss the possibility of labeled metabolites in brain. Metabolite accumu lation in brain may be important for some tracers, although the NMSP metabolites seem to be negli gible (Arnett et aI., 1985) .
The use of the ratio of radioactivities in a region of interest (e.g., caudate) and in an "inert" region (e.g., cerebellum) as an index of the binding of li gands to receptors evolved from the labeling of neuroreceptors in rodents in vivo [for a summary of pertinent publications, see Wong et al. (1984, refs. 3, 5] . In what circumstances does a ratio index yield a faithful estimate of k3? After the onset of steady state (T > To), the ratio can be obtained by dividing Eq. 17 by Eq. 18:
which describes a straight line with ordinate inter cept V?(1 + p)!X.2 and slope k3 Vr/x.. When V f is close to x., i.e., when binding is slow and k3 there fore negligible compared with k2' k3 can be esti mated as the slope of Eq. 28. On the other hand, when "additional, " secondary binding is known to be negligible and p is therefore zero, then k3 can be estimated as the slope of Eq. 28 divided by the square root of the ordinate intercept. Equation 2 8 cannot be used to estimate k3 when neither of these conditions is fulfilled. Thus, in the case of NMSP, which probably binds reversibly to S2 serotonin re ceptors in the striatum, Eq. 28 yields an index of k3 that depends on the magnitude of the distribution space in the region of interest in addition to the other factors that determine k3 (kon and B:nax). Wong et al. (1984) arrived at an index of k3 by recording the VcnlVocn ratio as a function of ac tual time rather than of 8(n. The striking linearity of this function in both normal volunteers and pa tients with neuropsychiatric disease is due in part to a fortuitously simple relationship between 8cn and T. When real time is substituted into Eq. 28,
which describes a straight line with slope Vrk38(nl AT when the ratio between 8(n and T is constant.
The relationship between 8Cn and T can be con stant when Ca(n approximates a power function of the form aT-b. When that is the case, then 8(T)IT equals 11(1 -b) and the slope equals k3 V clA(l -b).
However, this linearity between 8T and T is irrele vant for the general model presented here. Patlak and Blasberg (1985) suggested substituting the radioactivity recorded in an "inert" region for the radioactivity in the circulation. When the ratio between radioactivity in the "inert" region and blood Cplasma) was constant, Eq. 29 simply modi fied to (30) where 8jCn is the normalized integral of the radio activity recorded in the "inert" region (i. e. , cere bellum). The slope of this relationship is k3 Vr8(nl A8j(n when the 8Cn/8j(n ratio is constant. Re sults of the use of Eqs. 28-30 to determine ratio indexes were listed in Ta ble 2 and compared with values predicted from the results listed in Ta ble 1. The indexes differed from the correct value of k3 because the magnitude of k3 was significant com pared with the magnitude of k2 and because the value of p exceeded zero.
Thus, in cases in which the magnitude of k3 is not negligible compared with that of k2 and where me tabolites may cross into the cerebellum, it is neces sary to obtain plasma concentrations directly to es timate the transfer constants rather than record only the concentrations in the cerebellum as sug gested by Patlak and Blasberg (1985) . When a li gand binds irreversibly, we prefer the steady-state solution introduced in this article. If the metabo lites do not bind irreversibly to the receptors of in terest and bind in approximately equivalent amounts to binding and nonbinding regions, then the metabolite correction procedure is valid. The complete kinetic analysis is the only correct method when the magnitude of k3 is not negligible compared with that of k2 and when metabolites are present in tissue. In the companion article , we describe how the value of k3 is used to estimate the receptor density (Bmax) .
